Home > News > PSivida losses almost all due to R&D
August 30th, 2004
PSivida losses almost all due to R&D
Abstract:
pSivida Limited (PSD) today reported that after deducting outside equity interest they had recorded a loss attributable to the members of pSivida of $3.6 million for financial year ending 30 June 2004, compared to a loss of $2.7 million in 2003. The consolidated entity of the global nanotechnology company incurred a net loss of $7.5 million, compared to $5.3 million in 2003. The operating loss includes $7,million in research and development costs expended by pSiMedica and administrative expenses totalling $888,961.
Source:
egoli
Bookmark:
| Related News Press |
Financial Reports
Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results April 16th, 2021
Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results April 16th, 2021
 |
||
 |
||
| The latest news from around the world, FREE | ||
 |
||
|
|
||
| Premium Products | ||
 |
||
|
Only the news you want to read!
Learn More |
||
 |
||
|
Full-service, expert consulting
Learn More |
||
|
|
||